AbbVie (ABBV) announced the launch of PRODUODOPA in the European Union for the treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia, and when available combinations of Parkinson's medicinal products have not given satisfactory results. The company noted that the launch was supported by three studies: the Phase 3, 12-month open label study; the Phase 3, 12-week study; and a Phase 1 pharmacokinetic comparability study.
AbbVie was granted marketing authorization of PRODUODOPA in the third quarter of 2022. The VYAFUSER pump for the subcutaneous delivery of PRODUODOPA received CE Mark in November of 2023.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.